Thrombovision Named to Most Promising Life Science Technology Companies List



HOUSTON, June 19, 2007 ----- ThromboVision, Inc., a Houston-based biomedical diagnostics company, has been named one of the 10 Most Promising Life Science Technology Companies.   The companies were selected at the 6th Annual Life Science Technology Venture Forum, held on June 6 and sponsored by the Rice Alliance for Technology & Entrepreneurship of Rice University.

According to an announcement from the Rice Alliance, 34 emerging life science companies presented their elevator pitches to a hand-selected panel of investors and business leaders.  The announcement characterized ThromboVision thus:
“ThromboVision, Inc. provides easy-to-use, rapid-response, cost-effective and versatile point-of-care clinical diagnostic discoveries that advance medical diagnosis.”

More than 425 investors, venture capitalists, business leaders, and entrepreneurs attended the forum. 

ThromboVision is developing the groundbreaking ThromboGuide® Platelet Function Analyzer (T-Guide®).  The company will soon begin clinical trails using an advanced T-Guide prototype.

The T-Guide® is a risk assessment / risk modification platelet function blood test that consists of a disposable test kit and a point-of-care base unit. The system will help physicians individualize antiplatelet therapy that they use to prevent heart attacks, strokes and stent occlusions. ThromboVision has licensed the patented technology developed by scientists affiliated with the Utah Artificial Heart Research Institute, Brigham Young University and the University of Utah.


ThromboVision, Inc. is a biomedical company committed to enabling people to lead longer and healthier lives. ThromboVision provides easy-to-use, rapid-response, cost-effective, and versatile point-of-care clinical diagnostic discoveries that advance medical diagnosis.  The company’s products will improve medical care by assisting physicians in diagnosing and managing critical cardiovascular risk factors, especially those related to platelet function and antiplatelet drug therapy.

ThromboVision is a Houston Technology Center (HTC) client company.  HTC is a business accelerator that assists Houston-based emerging technology companies in key sectors such as Energy, Information Technology, Life Sciences, Nanotechnology and NASA-originated technologies.


This release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Statements in this release regarding ThromboVision’s business that are not historical facts are “forward-looking statements,” which involve risks and uncertainties that could cause actual results to differ materially from any future results, performance, or achievements expressed or implied by such statements.

Author: Edward R. Teitel, MD 713.491.4449 OR Sally I Evans, APR 713.660.7990 or 713.557.2461
Phone: (713) 491-4449
Category: recent news | Sub Category: client companies